Peer Recovery Support in the Homeless Health Care Setting
NCT07931430, Not applicable, Not yet recruiting, Massachusetts General Hospital
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Peer Recovery Support in the Homeless Health Care Setting | ClinicalTrials.gov |
| NCT number | NCT07931430 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 40 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Massachusetts General Hospital | ClinicalTrials.gov |
| Conditions | Opioid Use Disorder | ClinicalTrials.gov |
| Interventions | Peer support | ClinicalTrials.gov |
| First posted | 2026-11-12 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Recruitment rate | During recruitment period | Proportion of eligible individuals who enroll in the study, calculated as the number of enrolled participants divided by the number of eligible individuals screened. | ClinicalTrials.gov |
| Primary | Randomization rate | At enrollment | Proportion of enrolled participants who are successfully randomized to a study arm, calculated as the number of randomized participants divided by the total number enrolled. | ClinicalTrials.gov |
| Primary | Study retention rate | 90-day follow-up (days 90-105 after randomization). | Proportion of randomized participants who complete the 90-day follow-up survey, calculated as the number completing the follow-up survey divided by the total number randomized. | ClinicalTrials.gov |
| Primary | Client Satisfaction Questionnaire Score | 90-day follow-up (days 90-105 after randomization) | Intervention acceptability will be assessed among participants randomized to the peer recovery support intervention using the 8-item Client Satisfaction Questionnaire (CSQ-8). Scores range from 8 to 32, with higher scores indicating greater satisfaction with services received. | ClinicalTrials.gov |
| Primary | Number of Completed Peer Support Sessions | Randomization through day 90 | Total number of completed peer support sessions per intervention participant during the 90-day period. | ClinicalTrials.gov |
| Secondary | Retention in Office-Based Addiction Treatment (OBAT) at 90 Days | Days 75-105 following enrollment | Proportion of participants with at least one completed in-person or virtual OBAT clinical encounter between days 75 and 105 following the baseline visit, assessed using electronic health record data. | ClinicalTrials.gov |
| Secondary | Self-Reported Buprenorphine Adherence | Past 30 days at the 90-day follow-up | Number of days covered by buprenorphine during the 30 days preceding the 90-day follow-up, assessed using the Timeline Followback (TLFB) method. Possible values range from 0 to 30 days, with higher values indicating greater medication coverage. | ClinicalTrials.gov |
| Secondary | Buprenorphine Percent of Days Covered | Enrollment through day 90 | Percentage of days covered by buprenorphine during the 90-day study period, calculated using electronic health record medication data. Values range from 0% to 100%, with higher values indicating greater medication coverage. | ClinicalTrials.gov |
| Secondary | Past 30-Day Non-Prescribed Opioid Use | Past 30 days at the 90-day follow-up. | Number of days of non-prescribed opioid use during the 30 days preceding the 90-day follow-up, assessed using the Timeline Followback (TLFB) method. Possible values range from 0 to 30 days, with higher values indicating more frequent opioid use. | ClinicalTrials.gov |
| Secondary | Change in Opioid Use Severity | Baseline and 90-day follow-up | Change in opioid use severity from baseline to the 90-day follow-up, assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS)-based opioid use severity score. Higher scores indicate greater opioid use severity. | ClinicalTrials.gov |
| Secondary | Change in Recovery | Baseline and 90-day follow-up | Change in recovery from baseline to the 90-day follow-up, assessed using the Substance Use Recovery Evaluator (SURE) total score. Higher scores indicate greater recovery. | ClinicalTrials.gov |
| Secondary | Change in Emotional Support | Baseline and 90-day follow-up | Change in perceived emotional support from baseline to the 90-day follow-up, assessed using the 4-item PROMIS Emotional Support Short Form. Higher scores indicate greater perceived emotional support. | ClinicalTrials.gov |
| Secondary | Change in Instrumental Support | Baseline and 90-day follow-up | Change in perceived instrumental support from baseline to the 90-day follow-up, assessed using the 4-item PROMIS Instrumental Support Short Form. Higher scores indicate greater perceived instrumental support. | ClinicalTrials.gov |
| Secondary | Change in Informational Support | Baseline and 90-day follow-up | hange in perceived informational support from baseline to the 90-day follow-up, assessed using the 4-item PROMIS Informational Support Short Form. Higher scores indicate greater perceived informational support. | ClinicalTrials.gov |
| Secondary | Change in Companionship | Baseline and 90-day follow-up | Change in perceived companionship from baseline to the 90-day follow-up, assessed using the 4-item PROMIS Companionship Short Form. Higher scores indicate greater perceived companionship. | ClinicalTrials.gov |
| Other | Duration of Peer Support Sessions | Randomization through day 90 | Duration in minutes of completed peer support sessions, summarized across intervention participants. | ClinicalTrials.gov |
| Other | Delivery of Intervention Components | Randomization through day 90 | Frequency with which prespecified peer support intervention components are documented as delivered, based on the Peer Support Contact and Fidelity Log. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)